Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 1-year consensus price objective of $10.00 for the company and are predicting that the company will post ($0.01) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Kitov Pharmaceuticals an industry rank of 175 out of 265 based on the ratings given to its competitors.
Separately, HC Wainwright raised shares of Kitov Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Tuesday, November 21st.
Kitov Pharmaceuticals Company Profile
Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kitov Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.